North America Sickle Cell Disease Market, By Disease Type, By Drug Type, By Distribution Channel

Description

North America Sickle Cell Disease Market is estimated to be valued at USD 1,400.2 Mn in 2025 and is expected to reach USD 4,005.3 Mn by 2032, growing at a compound annual growth rate (CAGR) of 16.2% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 1,400.2 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	16.20%	2032 Value Projection:	USD 4,005.3 Mn

Sickle cell disease (SCD) is a group of inherited red blood cell disorders, in which the red blood cells of the individuals become sticky and almost 'C' or curved in the shape and therefore the disease is known as sickle cell disease. The sickle cell diseases include sickle cell anemia, sickle cell beta- thalassemia, sickle Hemoglobin C Disease, and others. The various symptoms associated with the sickle cell diseases include anemia, episodes of pain, swelling of hands and feet, and others. Major side effects of hydroxyurea on the long-term treatment in patients suffering from sickle cell disease are gastrointestinal effects such as gastric distress, gastritis, mucositis, and oral mucosa ulcer, dermatological effects such as painful skin ulcers, aphthous ulcers, non-ulcerative toxicity with erythema, and skin infiltration, it can also decrease sperm count and sperm motility in males and can even cause severe interstitial pneumonia. The treatment of the sickle cell disease includes medications and blood transfusions. In some cases of the children and teenagers, a stem cell transplant might also cure the disease.

Market Dynamics

The increasing product approvals by key players for the treatment of sickle cell disease is expected to drive the growth of the North America sickle cell disease market over the forecast period. For instance, in May 2021, Chiesi Farmaceutici S.p.A., a pharmaceutical company, announced that the company had received the U.S. Food Drug and Administration approval for FERRIPROX (deferiprone) indicated for the treatment of transfusional iron overload due to sickle cell disease (SCD) and anemia in pediatric patients of three years old or older and adults.

Key features of the study:

This report provides in-depth analysis of the North America sickle cell disease market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the North America sickle cell disease market based on the following parameters - company highlights, types portfolio, key highlights, financial performance, and market strategies
Key companies covered as a part of this study include Novartis International AG, Bristol-Myers Squibb Company, Bluebird Bio, Global Blood Therapeutics, Inc., Pfizer Inc., Emmaus Life Sciences, Inc., ADDMEDICA, Sangamo Therapeutics, Inc., Acceleron Pharma, Inc., Agios Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals, Inc., and Imara, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The North America sickle cell disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the North America sickle cell disease market

Detailed Segmentation:

North America Sickle Cell Disease Market, By Disease Type:
- Sickle Cell Anemia
- Sickle Beta Thalassemia
- Sickle Hemoglobin C Disease
North America Sickle Cell Disease Market, By Drug Type:
- Hydroxyurea
- L-glutamine
- Crizanlizumab
- Pain-relievers
- Voxelotor
- Others
North America Sickle Cell Disease Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
North America Sickle Cell Disease Market, By Country:
- U.S.
- Canada
Company Profiles
- Novartis International AG
- Bristol-Myers Squibb Company
- Bluebird Bio
- Global Blood Therapeutics, Inc.
- Pfizer Inc.
- Emmaus Life Sciences, Inc.
- ADDMEDICA
- Sangamo Therapeutics, Inc.
- Acceleron Pharma, Inc.
- Agios Pharmaceuticals, Inc.
- Chiesi Farmaceutici S.p.A.
- Vertex Pharmaceuticals, Inc.
- Imara, Inc.

Product Code: CMI4510

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Disease Type
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Country
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics

Drivers
Restraints
Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- PORTER'S Analysis
- Pipeline Analysis

4. North America Sickle Cell Disease Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. North America Sickle Cell Disease Market, By Disease Type, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Sickle Cell Anemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Sickle Beta Thalassemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Sickle Hemoglobin C Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends

6. North America Sickle Cell Disease Market, By Drug Type, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Hydroxyurea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
L-glutamine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Crizanlizumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Pain-relievers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Voxelotor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends

7. North America Sickle Cell Disease Market, By Distribution Channel, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

8. North America Sickle Cell Disease Market, By Country, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
U.S.
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (US$ Mn)
Canada
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (US$ Mn)

9. Competitive Landscape

Company Profiles
- Novartis International AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Bristol-Myers Squibb Company
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Global Blood Therapeutics, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Emmaus Life Sciences, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- ADDMEDICA
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sangamo Therapeutics, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Acceleron Pharma, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Agios Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Chiesi Farmaceutici S.p.A.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Vertex Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- IMARA, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- CRISPR Therapeutics
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Scribe Therapeutics Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Fulcrum Therapeutics, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- HPC International
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Editas Medicine, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Nicox SA
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Fera Pharmaceuticals
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Tessera Therapeutics
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies

10. Section

References
Research Methodology
About us and Sales Contact